{
  "claim_id": "claim_004",
  "claim": "Vaccination with a higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
  "document": "Arunachalam_et_al.__2021_",
  "verified_evidence": [
    {
      "id": 1,
      "quote": "Recently Richards et al.65 examined CD4 T-cell and antibody responses in healthy adults who received egg derived split vaccine, cell derived split vaccine or RIV4 for three successive influenza seasons (2015-2016, 2016-2017, and 2017-2018 65. RIV4 elicited the most robust responses, with significantly higher T-cell and antibody levels than the other two vaccines. Authors postulated that simpler glycosylation of rHA and absence of other influenza viral proteins in RIV4 contributed to the observed robust immune response for RIV4 and emphasised the relevance of these features in determining vaccine efficacy and long term immunity 65.",
      "supports_claim": true,
      "explanation": "The quote directly compares the immune responses (including antibody levels) induced by RIV4 (a higher-dose recombinant flu vaccine) and standard egg-based vaccines, stating that RIV4 elicited 'significantly higher T-cell and antibody levels than the other two vaccines.' This directly supports the claim that vaccination with a higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
      "presence_explanation": "The quote appears on page 5 of the document, with only minor differences in wording and formatting. The factual content is preserved: 'Recently Richards et al.65 examined CD4 T-cell and antibody responses in healthy adults who received egg derived split vaccine, cell derived split vaccine or RIV4 for three successive influenza seasons (2015-2016, 2016-2017, and 2017-2018 65. RIV4 elicited the most robust responses, with significantly higher T-cell and antibody levels than the other two vaccines. Authors postulated that simpler glycosylation of rHA and absence of other influenza viral proteins in RIV4 contributed to the observed robust immune response for RIV4 and emphasised the relevance of these features in determining vaccine efficacy and long term immunity 65.' The quote in the prompt is a faithful representation of the content in the document.",
      "support_explanation": "The quote directly compares the immune responses (including antibody levels) induced by RIV4 (a higher-dose recombinant flu vaccine) and standard egg-based vaccines, stating that RIV4 elicited 'significantly higher T-cell and antibody levels than the other two vaccines.' This directly supports the claim that vaccination with a higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
      "original_relevance": "This quote directly compares the antibody responses induced by the higher-dose recombinant vaccine (RIV4) and standard egg-based vaccines, showing that RIV4 produced significantly higher antibody levels, supporting the claim."
    },
    {
      "id": 2,
      "quote": "Portnoff et al.64 demonstrated that recombinant HA antigens (specifically for the H3 strain) produced using BEVS (as used for RIV4), induced significantly higher levels of broadly cross reactive antibodies against highly conserved regions of the HA head and stem domains than egg derived split vaccines 64.",
      "supports_claim": true,
      "explanation": "The quote directly compares recombinant HA antigens (as used in RIV4, a higher-dose recombinant flu vaccine) to egg-derived split vaccines, stating that the recombinant vaccine induced 'significantly higher levels of broadly cross reactive antibodies.' This directly supports the claim that vaccination with a higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
      "presence_explanation": "The quote appears on page 5 of the document: 'Portnoff et al.64 demonstrated that recombinant HA antigens (specifically for the H3 strain) produced using BEVS (as used for RIV4), induced significantly higher levels of broadly cross reactive antibodies against highly conserved regions of the HA head and stem domains than egg derived split vaccines 64.' The wording and factual content are semantically equivalent to the quote provided.",
      "support_explanation": "The quote directly compares recombinant HA antigens (as used in RIV4, a higher-dose recombinant flu vaccine) to egg-derived split vaccines, stating that the recombinant vaccine induced 'significantly higher levels of broadly cross reactive antibodies.' This directly supports the claim that vaccination with a higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
      "original_relevance": "This quote provides evidence that the recombinant vaccine induces higher levels of antibodies compared to egg-based vaccines, supporting the claim of a more robust antibody response."
    },
    {
      "id": 3,
      "quote": "Higher magnitudes of haem agglutination inhibitory antibody response against HA1 have also been observed with RIV4 compared to egg- or mammalian cell derived split vaccines (Flu cel vax Tetra, Seqirus, and Fluzone quadrivalent SD, Sanofi Pasteur 60.",
      "supports_claim": true,
      "explanation": "The quote directly states that RIV4 (a recombinant quadrivalent influenza vaccine) induces higher magnitudes of haemagglutination inhibitory antibody response against HA1 compared to egg- or mammalian cell derived split vaccines, which include standard-dose egg-based vaccines. This directly supports the claim that higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
      "presence_explanation": "A semantically equivalent quote appears on page 5: 'Higher magnitudes of haem agglutination inhibitory antibody response against HA1 have also been observed with RIV4 compared to egg- or mammalian cell derived split vaccines (Flu cel vax Tetra, Seqirus, and Fluzone quadrivalent SD, Sanofi Pasteur 60.' The factual content, technical terms, and vaccine names match the quote to verify, with only minor formatting differences (e.g., 'haem agglutination' vs 'haem agglutination', and the vaccine names are the same).",
      "support_explanation": "The quote directly states that RIV4 (a recombinant quadrivalent influenza vaccine) induces higher magnitudes of haemagglutination inhibitory antibody response against HA1 compared to egg- or mammalian cell derived split vaccines, which include standard-dose egg-based vaccines. This directly supports the claim that higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
      "original_relevance": "This quote explicitly states that RIV4 (a higher-dose recombinant vaccine) elicits higher antibody responses than standard egg-based vaccines, directly supporting the claim."
    },
    {
      "id": 4,
      "quote": "In a small study by Belongia et al.82, participants aged 65-74 years were immunised with RIV4, a high dose split virion inactivated trivalent influenza vaccine (Fluzone High Dose, Sanofi Pasteur; HD-IIV3) or adjuvanted-IIV3 (aIIV3)82. Participant sera were tested against four A/H3N2 viruses including a cell propagated reference vaccine strain, two circulating viruses and an antigenically advanced virus with evidence of antigenic drift. The post vaccination geometric mean fold rise against the two circulating viruses was twice as high for RIV4 as for HD-IIV3 or aIIV3.",
      "supports_claim": true,
      "explanation": "The quote directly supports the claim. It reports that in a study, the antibody response (measured by geometric mean fold rise) against two circulating A/H3N2 viruses was twice as high for the higher-dose recombinant vaccine (RIV4) compared to both high-dose and adjuvanted egg-based vaccines (HD-IIV3 and aIIV3). This provides explicit comparative data showing a more robust antibody response from the recombinant vaccine, as claimed.",
      "presence_explanation": "The quote appears on page 5 of the document, with only minor differences in formatting and wording (e.g., 'antigenically' vs 'antigenic ally', 'Sanofi Pasteur' vs 'SanofiPasteur'). The factual content, including the study by Belongia et al., the age group (65-74 years), the vaccines compared (RIV4, HD-IIV3, aIIV3), the testing against four A/H3N2 viruses, and the key result ('The post vaccination geometric mean fold rise against the two circulating viruses was twice as high for RIV4 as for HD-IIV3 or aIIV3'), is preserved and matches the quote to verify.",
      "support_explanation": "The quote directly supports the claim. It reports that in a study, the antibody response (measured by geometric mean fold rise) against two circulating A/H3N2 viruses was twice as high for the higher-dose recombinant vaccine (RIV4) compared to both high-dose and adjuvanted egg-based vaccines (HD-IIV3 and aIIV3). This provides explicit comparative data showing a more robust antibody response from the recombinant vaccine, as claimed.",
      "original_relevance": "This quote provides direct comparative data showing that the antibody response (measured by geometric mean fold rise) was twice as high for the recombinant vaccine (RIV4) compared to high-dose and adjuvanted egg-based vaccines, strongly supporting the claim."
    },
    {
      "id": "comp_1",
      "quote": "In a study by Nachbagauer et al.78, RIV4 induced HA stem specific neutralising antibodies directed against influenza subtypes H1, H3 and B haemagglutinin in an age dependent manner in humans, with the highest titres observed in the elderly 78. RIV4 also induces antibodies, in both humans and mice, that are specific to epitopes in the HA head region, at greater proportions than a traditional mammalian cell derived subunit vaccine (Flucelvax [Trivalent] 77.",
      "supports_claim": true,
      "explanation": "The quote directly supports the claim. It states that RIV4 (a higher-dose recombinant flu vaccine) induces HA stem-specific neutralising antibodies in humans, with the highest titres in the elderly, and that RIV4 induces antibodies to HA head epitopes at greater proportions than a traditional mammalian cell-derived subunit vaccine. This provides direct evidence that RIV4 may induce a more robust antibody response than standard-dose, egg-based (or cell-based) vaccines, as claimed.",
      "presence_explanation": "The quote is found on page 5 of the document, with only minor differences in formatting and word order, but all key facts and technical content are preserved. The document states: 'In a study by Nachbagauer et al.78, RIV4 induced HA stem specific neutralising antibodies directed against influenza subtypes H1, H3 and B haemagglutinin in an age dependent manner in humans, with the highest titres observed in the elderly 78. RIV4 also induces antibodies, in both humans and mice, that are specific to epitopes in the HA head region, at greater proportions than a traditional mammalian cell derived subunit vaccine (Flucelvax [Trivalent] 77.' This matches the quote to verify.",
      "support_explanation": "The quote directly supports the claim. It states that RIV4 (a higher-dose recombinant flu vaccine) induces HA stem-specific neutralising antibodies in humans, with the highest titres in the elderly, and that RIV4 induces antibodies to HA head epitopes at greater proportions than a traditional mammalian cell-derived subunit vaccine. This provides direct evidence that RIV4 may induce a more robust antibody response than standard-dose, egg-based (or cell-based) vaccines, as claimed.",
      "original_relevance": "This quote provides direct evidence that RIV4 (a higher-dose recombinant flu vaccine) induces higher levels of specific antibodies, including in the HA head and stem regions, compared to a traditional (egg- or cell-based) vaccine, supporting the claim of a more robust antibody response."
    }
  ],
  "verification_stats": {
    "total_verified": 5
  },
  "image_evidence": []
}